“showed a trend”

The improvement over NT-proBNP showed a trend ( P = .07).

While HRQoL increased in all patients, obese patients showed a trend towards an even greater improvement of mental HRQoL ( p = 0.07) vs. non- obese patients.

Pre-specified analysis of HPS2-THRIVE based on sex showed a trend towards worse CV outcomes in women treated with niacin ( p = 0.07).

Liking factual text showed a trend to be associated with slower reaction times (β = 283.98, s.e. = 146.40, t = 1.94, p = 0.07).

Enh+ tumor samples showed a trend toward elevated methyl Lip ( P = .07), but there was no difference observed in tCho levels ( Table 2 ).

Patients with high baseline plasma VEGF-A levels showed a trend toward improved OS (HR = 0.72, 95% CI, 0.57–0.93), compared with those with low VEGF-A levels (HR = 1.01 [95% CI, 0.77–1.31], interaction P = 0.07).

However, one metabolite, serum N,N-Dimethylglycine, showed a trend (OR = 0.548, p = 0.070) indicating that higher values were associated with an increased chance of being a Non-responder.

Levene’s test for group differences in variance in CT in the Group MFG Cluster showed a trend towards a group difference (Levene’s statistic = 2.7, p = 0.07).

In addition, the VOC profiles from method 1 showed a trend of discrimination between asthmatics with versus without atopy (p=0.07), whereas such discrimination was not apparent using methods 1 and 2 (p>0.77).

The secondary endpoints, progression-free survival and AML-free survival were also investigated and showed a trend to a more favorable outcome for patients with elevated HbF: the median progression-free survival was 7.7 months versus 2.4 months (HR=0.32; 95% CI: 0.10–1.10; P =0.07) ( Figure 3B ) and the median AML-free survival was 13.1 months versus 7.6 months (HR=0.42; 95% CI: 0.13–1.38; P =0.15) ( Figure 3C ).

13 In the Comparison of Acute Treatments in Cancer Haemostasis (CATCH) trial, the largest phase III randomized trial comparing LMWH to WFR, patients treated with the tinzaparin showed a trend toward reduction in VTE recurrence (7.2% for tinzaparin vs. 10.5% for WFR; HR, 0.65; 95% CI, 0.41–1.03; P = 0.07), but the difference was not statistically significant.

The interaction of condition and gender showed a trend [ F (1,18) = 3.53, p = 0.07].

Using Flk1 GFP/+ (WT-Flk1) [ 17 ] and CXCL12 Gagtm/Gagtm :Flk1 GFP/+ (KI-Flk1) mice, which have green fluorescent endothelial cells (ECs), cytometric analysis also showed a trend to an increase in the number of muscle ECs in the KI-Flk1 mice when compared to the WT-Flk1 mice ( p = 0.07; Additional file 2 : Figure S1E).

A post-hoc comparison of the group exposed to clean air and the group exposed to fear chemosignals showed a trend level time x odour interaction during the second day of trial (F(1,45)=3.74, p=0.07).

The CFI increase in the CVP↓+ CO↑ group at initiation and 24 h after PICCO showed a trend that was not significant ( P = 0.07).

Pairwise comparisons showed a trend of Q2 > Q4 ( t (84) = 1.82, p = 0.070), which is reminiscent of previous findings ( Helfrich et al., 2018 ), but this result is not robust and should be treated as a negative finding.

Plasma levels of IL-4 were associated with the levels of intact proviral DNA (r=0.37, p=0.009), and the other main Th2 cytokine, IL-13, showed a trend towards a positive association with intact proviral DNA (r=0.26, p=0.07) (Table 1).

Furthermore, the highest of the specific IgE values at baseline to any of the foods in the participants’ OIT showed a trend to be important for the study outcome in the placebo arm (P = 0·07, FDR adjusted P = 0·19, appendix p 7), while this was not the case in the omalizumab arm.

Intervention had no effect on time to first exacerbation (HR 0.65, 95% CI 0.21 to 2.07, P = .24), but showed a trend toward a 39% decreased frequency of exacerbations (RR = 0.61, 95% CI 0.35 to 1.03, P = .070) for the adjusted models, respectively.

Patients with small lesions (maximum diameter <5 cm) showed a trend toward a higher OS rate ( p = 0.07).

Median palmar abduction, with 55.4° (10°) in the RA group, showed a trend to be better in prosthesis patients (57.9° (10°)) ( p = 0.07).

Moreover, SOX2-negative cases showed a trend for a longer survival time when compared to those expressing this factor (80 months (CI 69-92) vs 42 months (CI 25-59), respectively; HR 2,8; p = 0.07).

In support of this, Pol II signals showed a trend of increase at two of these enhancers ( p = 0.07–0.08) in response to FC (Supplementary Fig. 7a-c ), which are consistent with the earlier findings 16 ; although the Pol II difference between WT and Top3β-KO mice was not significant.

The mixed-model ANOVA analysis of P50 amplitude showed a trend toward a significant main effect of group ( F (1,25) = 3.58, p = 0.07) but no significant main effects of stimulus type or attention as well as no significant interactions between any of the factors ( Figure 2B ).

Both groups had comparable duration of ICU stay, but patients in the loading group showed a trend towards longer overall hospital stay (14.0 vs. 11.1 days, p = 0.07).